Ankylosing Spondylitis Insurance Denied? Appeal Guide

Why Insurers Deny Ankylosing Spondylitis Treatment

Ankylosing spondylitis (AS) — coded ICD-10 M45.0–M45.9 depending on spinal involvement — is a chronic inflammatory arthritis of the axial skeleton. Axial spondyloarthritis (axSpA) also includes non-radiographic axial SpA (nr-axSpA, ICD-10 M46.80). Treatment denials are extremely common, particularly for biologic and targeted synthetic DMARDs.

Step therapy failure requirements for biologics. The most common AS treatment denial involves biologics — TNF inhibitors (adalimumab/Humira, etanercept/Enbrel, infliximab/Remicade, certolizumab/Cimzia, golimumab/Simponi) and IL-17 inhibitors (secukinumab/Cosentyx, ixekizumab/Taltz). Insurers typically require documented failure on at least one, often two, conventional treatments (NSAIDs at maximum tolerated dose for a defined period) before approving biologics. If NSAID failure is not documented with dates and adequate dosing, the biologic will be denied.

Switching between biologics denied. When a patient fails one biologic due to inadequate response or intolerance and requires switching to another, insurers frequently deny the second biologic citing "insufficient documentation of failure." This is a clinical reality for AS — lack of response to one TNF inhibitor does not predict failure on another.

Not medically necessary — disease activity not documented. Insurers often require objective evidence of active disease: elevated CRP or ESR, BASDAI score above a threshold (typically 4 on a 0–10 scale), or MRI evidence of active sacroiliac joint inflammation. If lab values are normal (AS patients can have normal inflammatory markers) or the BASDAI was not formally scored, the claim is denied.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization requirements. Every biologic for AS requires prior authorization, renewed typically every 6–12 months. Missing reauthorization windows results in denied claims for continuation of a biologic that has been working.

Non-radiographic axSpA exclusions. Some plans cover biologics only for ankylosing spondylitis with confirmed radiographic sacroiliitis (modified New York criteria) and explicitly exclude nr-axSpA, even though FDA approvals for several biologics cover both diagnoses.

Your Legal Rights

• ACA Essential Health Benefits — Prescription drug benefits on ACA-compliant plans cover FDA-approved medications for AS. Biologics approved for AS must be covered, though formulary tier placement and step therapy vary.
• ERISA — For employer-sponsored plans, ERISA entitles you to a detailed explanation of the denial, access to the claims file and clinical criteria, and the right to appeal through a full and fair review process, with federal court access if appeals fail.
• State step therapy laws — Over 30 states have enacted step therapy reform laws requiring exceptions for patients where step therapy would cause harm or when a physician certifies that the required step therapy is inappropriate. Check your state's law at the National Alliance of Mental Illness (or through your state insurance department).
• External Independent Review: Complete Guide" class="auto-link">External review rights — After exhausting internal appeals, you are entitled to free external review by an independent rheumatologist. AS biologic denials are frequently overturned at external review with strong clinical documentation.
• Mental Health Parity Act (MHPAEA) Explained" class="auto-link">MHPAEA — Not directly applicable to AS (a physical condition), but relevant if you have co-occurring depression or anxiety associated with chronic pain.

Step-by-Step Appeal Strategy

Step 1: Understand the Exact Denial Criterion

Request the insurer's clinical policy bulletin for the specific biologic denied. Most insurers base AS biologic criteria on:

• Modified New York criteria (for radiographic AS) or ASAS criteria (for axSpA)
• BASDAI score ≥ 4 or ASDAS score ≥ 2.1
• Documented NSAID failure (typically 2 NSAIDs at maximum tolerated dose for ≥ 4 weeks each)
• Normal inflammatory markers alone are not sufficient to deny if clinical disease activity is documented

Identify whether the denial is for initial authorization or for continuation/switching of a biologic.

Step 2: Build Your Documentation Checklist

Gather before writing your appeal:

• ICD-10 diagnosis code: M45.x (ankylosing spondylitis) or M46.80 (nr-axSpA)
• Documentation meeting modified New York criteria or ASAS classification criteria
• Sacroiliac joint X-ray and/or MRI reports showing sacroiliitis or active bone marrow edema
• BASDAI or ASDAS scores documented in rheumatologist's notes
• HLA-B27 test result (positive supports AS diagnosis but not required)
• NSAID trial documentation: drug names, doses, durations, and reasons for discontinuation (failure, intolerance, contraindication)
• For biologic switching: documentation of why the prior biologic failed (lack of response with specific BASDAI/ASDAS before and after, or adverse event)
• Rheumatologist letter of medical necessity
• ACR/EULAR 2022 guidelines for axSpA recommending biologic therapy after NSAID failure
• If nr-axSpA: FDA-approved biologic indication for nr-axSpA (secukinumab, certolizumab, ixekizumab all have nr-axSpA indications)

Step 3: Write a Targeted Appeal Letter

Your appeal should:

• Reference the exact ICD-10 code and cite the classification criteria met (modified New York or ASAS)
• Document NSAID failure with specific drugs, doses, duration, and outcome — if NSAIDs were contraindicated (GI history, cardiac risk), cite the contraindication
• Present objective disease activity data (BASDAI/ASDAS scores, CRP/ESR) from rheumatologist notes
• Cite the 2022 ACR/SAA recommendations for the management of AS that support biologic therapy after NSAID failure
• If applicable, assert your state's step therapy exception law and request an exception based on your rheumatologist's clinical judgment
• Address the specific criterion the insurer cited in the denial

Step 4: Submit and Track

• Submit via certified mail and through the insurer's online portal
• Keep copies with delivery confirmation
• Calendar the response deadline (30 days standard, 72 hours expedited)
• Follow up in writing if no response

Step 5: Escalate

If the internal appeal fails:

• Request external review — An independent rheumatologist will evaluate the clinical evidence. AS biologic denials with strong BASDAI documentation and NSAID failure evidence are frequently overturned.
• Request peer-to-peer review — Your rheumatologist calls the insurer's medical director. This is often the fastest path to reversal for AS biologic denials.
• File a state insurance department complaint — Cite the step therapy reform law in your state if applicable.
• ERISA claim — For employer plans, consult a benefits attorney if the denial was not based on substantial evidence matching the plan's actual criteria.

Documentation Checklist Summary

Fight Back With ClaimBack

Ankylosing spondylitis treatment denials are among the most reversible in all of insurance — because the clinical evidence base is strong, the diagnostic criteria are objective, and the step therapy requirements are specific enough to document clearly. Whether your biologic was denied for incomplete NSAID trial documentation or because your insurer doesn't recognize nr-axSpA, a targeted appeal built around the right clinical evidence can win. ClaimBack generates a professional appeal letter in 3 minutes, citing the specific ASAS criteria, ACR guidelines, and state step therapy laws that apply to your AS treatment denial.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal